S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
A gold storm is coming… (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
A gold storm is coming… (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
A gold storm is coming… (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
A gold storm is coming… (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
A gold storm is coming… (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
A gold storm is coming… (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
A gold storm is coming… (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
A gold storm is coming… (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
NASDAQ:OCGN

Ocugen - OCGN Stock Forecast, Price & News

$1.29
-0.04 (-3.01%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.27
▼
$1.35
50-Day Range
$1.11
▼
$1.61
52-Week Range
$1.09
▼
$4.53
Volume
4.98 million shs
Average Volume
6.53 million shs
Market Capitalization
$282.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.40

Ocugen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
318.6% Upside
$5.40 Price Target
Short Interest
Bearish
20.37% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.22mentions of Ocugen in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$128,000 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.39) to ($0.42) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.60 out of 5 stars

Medical Sector

880th out of 1,028 stocks

Biological Products, Except Diagnostic Industry

139th out of 168 stocks

See Top Rated MarketRank™ Stocks Here
OCGN stock logo

About Ocugen (NASDAQ:OCGN) Stock

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Receive OCGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocugen and its competitors with MarketBeat's FREE daily newsletter.

OCGN Stock News Headlines

February 4, 2023 | finance.yahoo.com
1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell
February 1, 2023 | finance.yahoo.com
Ocugen Appoints Quan A. Vu as Chief Business Officer
February 5, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
January 31, 2023 | marketwatch.com
Ocugen Inc. stock rises Tuesday, outperforms market
January 31, 2023 | finance.yahoo.com
Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference
January 18, 2023 | seekingalpha.com
Ocugen: FDA Sector Head States Bridging Studies Insufficient
January 17, 2023 | markets.businessinsider.com
Mizuho Securities Reaffirms Their Buy Rating on Ocugen (OCGN)
January 17, 2023 | markets.businessinsider.com
Noble Financial Reaffirms Their Buy Rating on Ocugen (OCGN)
February 5, 2023 | Wall Street Watch Dogs (Ad)
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
January 9, 2023 | finance.yahoo.com
Ocugen Announces Encouraging Data From Late-Stage COVID-19 Vaccine Study
December 29, 2022 | finance.yahoo.com
Why Shares of Ocugen Jumped Thursday
December 15, 2022 | finance.yahoo.com
Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis
December 13, 2022 | finance.yahoo.com
Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell
December 7, 2022 | finance.yahoo.com
Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis
November 28, 2022 | finance.yahoo.com
Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit
November 9, 2022 | finance.yahoo.com
Why Ocugen Stock Wilted on Wednesday
November 8, 2022 | finance.yahoo.com
Ocugen Provides Business Update & Third Quarter 2022 Financial Results
November 7, 2022 | finance.yahoo.com
Ocugen, Inc.'s (NASDAQ:OCGN) largest shareholders are individual investors with 58% ownership, institutions own 40%
October 27, 2022 | finance.yahoo.com
Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results
October 20, 2022 | finance.yahoo.com
Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022 - Yahoo Finance
October 19, 2022 | globenewswire.com
Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022 - GlobeNewswire
October 19, 2022 | finance.yahoo.com
Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022
October 14, 2022 | globenewswire.com
Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2 - GlobeNewswire
October 13, 2022 | finance.yahoo.com
Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2 - Yahoo Finance
October 12, 2022 | finance.yahoo.com
Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2
October 7, 2022 | finance.yahoo.com
Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences - Yahoo Finance
October 6, 2022 | fool.com
Wall Street Thinks This Top 100 Robinhood Stock Could Skyrocket by 217% - The Motley Fool
See More Headlines
Receive OCGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocugen and its competitors with MarketBeat's FREE daily newsletter.

OCGN Company Calendar

Last Earnings
11/08/2022
Today
2/05/2023
Next Earnings (Estimated)
2/24/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OCGN
CUSIP
N/A
CIK
1372299
Web
ocugen.com
Phone
(484) 328-4701
Fax
781-547-4452
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.40
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$3.50
Forecasted Upside/Downside
+318.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.35)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-58,370,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-67.83%
Return on Assets
-59.94%

Debt

Debt-to-Equity Ratio
0.02
Current Ratio
7.21
Quick Ratio
7.21

Sales & Book Value

Annual Sales
$42.62 million
Price / Sales
6.63
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.48 per share
Price / Book
2.69

Miscellaneous

Outstanding Shares
218,890,000
Free Float
212,736,000
Market Cap
$282.37 million
Optionable
Not Optionable
Beta
3.85

Key Executives

  • Shankar MusunuriShankar Musunuri
    Chairman & Chief Executive Officer
  • Jessica Crespo
    CFO, Chief Accounting Officer & SVP-Finance
  • Arun Upadhyay
    Chief Scientific Officer
  • Robert J. Hopkins
    Chief Medical Officer
  • Nirdosh Jagota
    SVP-Regulatory Affairs, Compliance & Safety

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













OCGN Stock - Frequently Asked Questions

Should I buy or sell Ocugen stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocugen in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OCGN shares.
View OCGN analyst ratings or view top-rated stocks.

What is Ocugen's stock price forecast for 2023?

5 analysts have issued 12-month price targets for Ocugen's shares. Their OCGN share price forecasts range from $3.50 to $8.00. On average, they expect the company's share price to reach $5.40 in the next year. This suggests a possible upside of 318.6% from the stock's current price.
View analysts price targets for OCGN or view top-rated stocks among Wall Street analysts.

How have OCGN shares performed in 2023?

Ocugen's stock was trading at $1.30 at the start of the year. Since then, OCGN shares have decreased by 0.8% and is now trading at $1.29.
View the best growth stocks for 2023 here.

When is Ocugen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 24th 2023.
View our OCGN earnings forecast.

How were Ocugen's earnings last quarter?

Ocugen, Inc. (NASDAQ:OCGN) released its quarterly earnings data on Tuesday, November, 8th. The company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10).

What other stocks do shareholders of Ocugen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocugen investors own include Onconova Therapeutics (ONTX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), FuelCell Energy (FCEL), Biocept (BIOC), OPKO Health (OPK), Tonix Pharmaceuticals (TNXP), Actinium Pharmaceuticals (ATNM) and Carnival Co. & (CCL).

What is Ocugen's stock symbol?

Ocugen trades on the NASDAQ under the ticker symbol "OCGN."

Who are Ocugen's major shareholders?

Ocugen's stock is owned by many different retail and institutional investors. Top institutional investors include Bank of Montreal Can (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Christopher Dold, Daniel Purefoy, Junge Zhang, Kirsten Castillo, Manish Potti, Prabhavathi Fernandes, Ramesh Kumar, Sanjay Subramanian, Shankar Musunuri, Uday Kompella and Vijay Tammara.
View institutional ownership trends.

How do I buy shares of Ocugen?

Shares of OCGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ocugen's stock price today?

One share of OCGN stock can currently be purchased for approximately $1.29.

How much money does Ocugen make?

Ocugen (NASDAQ:OCGN) has a market capitalization of $282.37 million and generates $42.62 million in revenue each year. The company earns $-58,370,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.

How can I contact Ocugen?

Ocugen's mailing address is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. The official website for the company is ocugen.com. The company can be reached via phone at (484) 328-4701, via email at ir@ocugen.com, or via fax at 781-547-4452.

This page (NASDAQ:OCGN) was last updated on 2/5/2023 by MarketBeat.com Staff